NASDAQ:IMAB

I-Mab Competitors

$62.07

+3.31 (+5.63 %)

(As of 05/12/2021 04:30 PM ET)

Add

Compare

Today's Range

$58.71

▼

$62.13

50-Day Range

$44.38

▼

$64.43

52-Week Range

$17.86

▼

$65.94

Volume650,921 shs

Average Volume367,591 shs

Market Capitalization$4.49 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

I-Mab (NASDAQ:IMAB) Vs. ALNY, ELAN, BMRN, ZLAB, GRFS, and RDY

Should you be buying IMAB stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to I-Mab, including Alnylam Pharmaceuticals (ALNY), Elanco Animal Health (ELAN), BioMarin Pharmaceutical (BMRN), Zai Lab (ZLAB), Grifols (GRFS), and Dr. Reddy's Laboratories (RDY).

I-Mab vs. Alnylam Pharmaceuticals Stock

Alnylam Pharmaceuticals (NASDAQ:ALNY) and I-Mab (NASDAQ:IMAB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares Alnylam Pharmaceuticals and I-Mab's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$219.75 million	71.33	$-886,120,000.00	($8.11)	-16.44
I-Mab	$4.31 million	1,042.73	$-208,560,000.00	($28.90)	-2.15

I-Mab has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alnylam Pharmaceuticals and I-Mab's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	-222.19%	-65.96%	-31.38%
I-Mab	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Alnylam Pharmaceuticals and I-Mab, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0	8	8	0	2.50
I-Mab	0	0	4	0	3.00

Alnylam Pharmaceuticals presently has a consensus price target of $168.7333, indicating a potential upside of 26.52%. I-Mab has a consensus price target of $70.00, indicating a potential upside of 12.78%. Given Alnylam Pharmaceuticals' higher possible upside, equities analysts clearly believe Alnylam Pharmaceuticals is more favorable than I-Mab.

Insider & Institutional Ownership

92.4% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 16.6% of I-Mab shares are held by institutional investors. 3.5% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

I-Mab beats Alnylam Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

I-Mab vs. Elanco Animal Health Stock

Elanco Animal Health (NYSE:ELAN) and I-Mab (NASDAQ:IMAB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares Elanco Animal Health and I-Mab's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$3.07 billion	4.94	$67.90 million	$1.06	30.28
I-Mab	$4.31 million	1,042.73	$-208,560,000.00	($28.90)	-2.15

Elanco Animal Health has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Elanco Animal Health and I-Mab's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-8.45%	3.43%	2.04%
I-Mab	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Elanco Animal Health and I-Mab, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1	3	9	0	2.62
I-Mab	0	0	4	0	3.00

Elanco Animal Health presently has a consensus price target of $32.2273, indicating a potential upside of 0.40%. I-Mab has a consensus price target of $70.00, indicating a potential upside of 12.78%. Given I-Mab's stronger consensus rating and higher possible upside, analysts clearly believe I-Mab is more favorable than Elanco Animal Health.

Insider & Institutional Ownership

86.8% of Elanco Animal Health shares are held by institutional investors. Comparatively, 16.6% of I-Mab shares are held by institutional investors. 0.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Elanco Animal Health beats I-Mab on 8 of the 13 factors compared between the two stocks.

I-Mab vs. BioMarin Pharmaceutical Stock

BioMarin Pharmaceutical (NASDAQ:BMRN) and I-Mab (NASDAQ:IMAB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares BioMarin Pharmaceutical and I-Mab's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$1.70 billion	8.11	$-23,850,000.00	$0.07	1,080.00
I-Mab	$4.31 million	1,042.73	$-208,560,000.00	($28.90)	-2.15

BioMarin Pharmaceutical has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioMarin Pharmaceutical and I-Mab's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	45.74%	4.34%	2.84%
I-Mab	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations and price targets for BioMarin Pharmaceutical and I-Mab, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	0	7	10	0	2.59
I-Mab	0	0	4	0	3.00

BioMarin Pharmaceutical presently has a consensus price target of $118.20, indicating a potential upside of 56.35%. I-Mab has a consensus price target of $70.00, indicating a potential upside of 12.78%. Given BioMarin Pharmaceutical's higher possible upside, equities analysts clearly believe BioMarin Pharmaceutical is more favorable than I-Mab.

Insider & Institutional Ownership

97.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 16.6% of I-Mab shares are held by institutional investors. 2.2% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

BioMarin Pharmaceutical beats I-Mab on 11 of the 13 factors compared between the two stocks.

I-Mab vs. Zai Lab Stock

Zai Lab (NASDAQ:ZLAB) and I-Mab (NASDAQ:IMAB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Profitability

This table compares Zai Lab and I-Mab's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zai Lab	N/A	N/A	N/A
I-Mab	N/A	N/A	N/A

Insider & Institutional Ownership

81.3% of Zai Lab shares are held by institutional investors. Comparatively, 16.6% of I-Mab shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations and price targets for Zai Lab and I-Mab, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	0	0	5	0	3.00
I-Mab	0	0	4	0	3.00

Zai Lab presently has a consensus price target of $197.8460, indicating a potential upside of 35.92%. I-Mab has a consensus price target of $70.00, indicating a potential upside of 12.78%. Given Zai Lab's higher possible upside, equities analysts clearly believe Zai Lab is more favorable than I-Mab.

Valuation and Earnings

This table compares Zai Lab and I-Mab's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$12.98 million	1,061.81	$-195,070,000.00	($3.03)	-48.04
I-Mab	$4.31 million	1,042.73	$-208,560,000.00	($28.90)	-2.15

Zai Lab has higher revenue and earnings than I-Mab. Zai Lab is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Summary

Zai Lab beats I-Mab on 7 of the 8 factors compared between the two stocks.

I-Mab vs. Grifols Stock

I-Mab (NASDAQ:IMAB) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Profitability

This table compares I-Mab and Grifols' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Grifols	12.79%	10.65%	4.79%

Insider & Institutional Ownership

16.6% of I-Mab shares are owned by institutional investors. Comparatively, 15.2% of Grifols shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for I-Mab and Grifols, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	0	0	4	0	3.00
Grifols	0	3	5	0	2.63

I-Mab currently has a consensus target price of $70.00, indicating a potential upside of 12.78%. Given I-Mab's stronger consensus rating and higher possible upside, research analysts clearly believe I-Mab is more favorable than Grifols.

Valuation & Earnings

This table compares I-Mab and Grifols' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$4.31 million	1,042.73	$-208,560,000.00	($28.90)	-2.15
Grifols	$5.71 billion	2.18	$700.16 million	$1.17	15.49

Grifols has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Summary

Grifols beats I-Mab on 8 of the 12 factors compared between the two stocks.

I-Mab vs. Dr. Reddy's Laboratories Stock

I-Mab (NASDAQ:IMAB) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Profitability

This table compares I-Mab and Dr. Reddy's Laboratories' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Dr. Reddy's Laboratories	8.23%	16.33%	10.79%

Insider & Institutional Ownership

16.6% of I-Mab shares are owned by institutional investors. Comparatively, 12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for I-Mab and Dr. Reddy's Laboratories, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	0	0	4	0	3.00
Dr. Reddy's Laboratories	0	0	3	0	3.00

I-Mab currently has a consensus target price of $70.00, indicating a potential upside of 12.78%. Dr. Reddy's Laboratories has a consensus target price of $70.00, indicating a potential downside of 2.06%. Given I-Mab's higher possible upside, research analysts clearly believe I-Mab is more favorable than Dr. Reddy's Laboratories.

Valuation & Earnings

This table compares I-Mab and Dr. Reddy's Laboratories' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$4.31 million	1,042.73	$-208,560,000.00	($28.90)	-2.15
Dr. Reddy's Laboratories	$2.32 billion	5.13	$259 million	$2.79	25.62

Dr. Reddy's Laboratories has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Dr. Reddy's Laboratories beats I-Mab on 8 of the 12 factors compared between the two stocks.